A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)
A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)
The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.
Inclusion Criteria:
Exclusion Criteria:
Miami, Florida 33136, United States
ABB, Buenos Aires F.D. C1199ABB, Argentina
Ramat Gan, Central District 5262100, Israel
Rome, Lazio 00168, Italy
Bunkyo-ku, Tokyo 113-8431, Japan
Shinjuku-ku, Tokyo 1608582, Japan
Lisbon, Lisbon District 1649-035, Portugal
Crownhill, Plymouth, PL6 8DH, United Kingdom